HARBOR INVESTMENT ADVISORY, LLC - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 471 filers reported holding CRISPR THERAPEUTICS AG in Q3 2021. The put-call ratio across all filers is 1.71 and the average weighting 0.2%.

Quarter-by-quarter ownership
HARBOR INVESTMENT ADVISORY, LLC ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2023$300,482
-19.2%
6,620
-0.1%
0.04%
-25.0%
Q2 2023$371,871
+14.6%
6,624
-7.7%
0.05%
+8.3%
Q1 2023$324,480
+1.4%
7,174
-8.9%
0.05%
-4.0%
Q4 2022$320,078
-56.0%
7,874
-29.2%
0.05%
-58.3%
Q3 2022$727,000
+5.7%
11,124
-1.8%
0.12%
+9.1%
Q2 2022$688,000
-3.6%
11,324
-0.4%
0.11%
+15.8%
Q1 2022$714,000
-39.4%
11,374
-26.8%
0.10%
-36.2%
Q4 2021$1,178,000
-34.5%
15,544
-3.3%
0.15%
-38.9%
Q3 2021$1,799,000
-32.2%
16,074
-2.0%
0.24%
-32.0%
Q2 2021$2,654,000
+35.8%
16,394
+2.2%
0.36%
+22.1%
Q1 2021$1,955,000
-16.9%
16,044
+4.4%
0.29%
-22.0%
Q4 2020$2,353,000
+97.6%
15,368
+7.9%
0.38%
+65.4%
Q3 2020$1,191,000
+16.1%
14,248
+2.1%
0.23%
+4.6%
Q2 2020$1,026,000
+134.8%
13,959
+35.5%
0.22%
+84.7%
Q1 2020$437,000
-24.5%
10,303
+8.5%
0.12%
-11.3%
Q4 2019$579,0009,4990.13%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q3 2021
NameSharesValueWeighting ↓
Gilfoyle Management LLC 150$6,37612.96%
Versant Venture Management, LLC 498,558$22,629,54812.03%
NEA Management Company, LLC 1,587,854$72,072,6935.57%
ARK Investment Management 7,163,118$325,133,9132.49%
Nikko Asset Management Americas, Inc. 3,465,470$157,263,0291.88%
Integral Health Asset Management, LLC 275,000$12,482,2501.73%
Merlin Capital, Inc 9,092$412,6861.54%
Del-Sette Capital Management, LLC 33,977$1,542,2161.52%
Green Alpha Advisors, LLC 34,880$1,583,2031.22%
Ikarian Capital, LLC 2,039$9,255,0211.11%
View complete list of CRISPR THERAPEUTICS AG shareholders